Table 1 Characteristics of participants with HIV viral loads ≥1000 copies/ml at enrolment by ART regimen line
Characteristic | All participants n (%) | ART regimen line | |
|---|---|---|---|
First line ART n (%) | Second line ART n (%) | ||
All (n, row %) | 110 | 74 (67.3) | 36 (32.7) |
Study site | |||
Entebbe | 90 (81.8) | 65 (87.8) | 25 (69.4) |
Kyamulibwa | 20 (18.2) | 9 (12.2) | 11 (30.6) |
Sex | |||
Females | 73 (66.4) | 53 (71.6) | 20 (55.6) |
Males | 37 (33.6) | 21 (28.4) | 16 (44.4) |
Age, years | |||
18–34 | 15 (13.6) | 6 (8.1) | 9 (25.0) |
35–49 | 72 (65.5) | 50 (67.6) | 22 (61.1) |
50+ | 23 (20.9) | 18 (24.3) | 5 (13.9) |
Body Mass Index (kg/m 2 ) a | |||
<18.5 | 15 (13.6) | 7 (9.5) | 8 (22.2) |
18.5–24.9 | 63 (57.3) | 44 (59.5) | 19 (52.8) |
25.0–29.9 | 20 (18.2) | 14 (18.9) | 6 (16.7) |
≥30 | 11 (10.0) | 8 (10.8) | 3 (8.3) |
HIV subtype | |||
A | 37 (33.6) | 25 (33.8) | 12 (33.3) |
B | 5 (4.5) | 3 (4.1) | 2 (5.6) |
C | 6 (5.5) | 5 (6.8) | 1 (2.8) |
D | 38 (34.5) | 22 (29.7) | 16 (44.4) |
CRF01_AE | 24 (21.8) | 19 (25.7) | 5 (13.9) |
CD4 cell counts at enrolment—cells/ml b | |||
≤350 | 65 (59.1) | 41 (55.4) | 24 (66.7) |
351–500 | 26 (23.6) | 22 (29.7) | 4 (11.1) |
501+ | 11 (10.0) | 5 (6.8) | 6 (16.7) |
Total duration on ART, years | |||
0–<5 | 15 (13.6) | 9 (12.2) | 6 (16.7) |
5–<9 | 6 (5.5) | 2 (2.7) | 4 (11.1) |
9+ | 89 (80.9) | 63 (85.1) | 26 (72.2) |
Duration on current ART regimen, years c | |||
<5 | 17 (15.5) | 9 (12.2) | 8 (22.2) |
5–<9 | 17 (15.5) | 2 (2.7) | 15 (41.7) |
9+ | 63 (57.3) | 63 (85.1) | 0 (0.0) |
Viral loads (copies/ml) | |||
1000–9999 | 43 (39.1) | 29 (39.2) | 14 (38.9) |
10,000+ | 67 (60.9) | 45 (60.8) | 22 (61.1) |